SAN FRANCISCO--(BUSINESS WIRE)--Bioluminescence Ventures (“BLV”), a biotech venture firm investing in next-generation medicines, today announced its emergence from stealth with $477M in assets under management across two funds: Bioluminescence Ventures Fund I, L.P., and Bioluminescence Ventures Fund II, L.P.

旧金山-（商业线）-生物发光投资公司（“BLV”）是一家投资于下一代药物的生物技术风险投资公司，今天宣布成立stealth公司，在两项资金中拥有4.77亿美元的管理资产：Bioluminescence Ventures Fund I，L.P。和Bioluminescence Ventures Fund II，L.P。

The firm is supported by an investor base that includes U.S. and multinational institutional Limited Partners. BLV has invested in multiple U.S. biotech companies to date. The firm will continue investing in transformative companies that are developing preventative, disease-modifying, and curative treatments for patients with major unmet medical needs..

该公司得到包括美国和跨国机构有限公司合作伙伴在内的投资者基地的支持。迄今为止，BLV已投资多家美国生物技术公司。该公司将继续投资于正在为主要未满足医疗需求的患者开发预防，改善疾病和治疗方法的转型公司。。

Bioluminescence Ventures was conceptualized to finance breakthrough platforms and support mission-driven leaders to develop first-in-class or best-in-class therapies – especially at a time when we are simultaneously experiencing both a golden age of biomedical innovation and the most difficult financing environment in a decade.

生物发光企业的概念化是为突破平台提供资金，并支持任务驱动的领导者开发一流或一流的疗法-特别是在我们同时经历生物医学创新的黄金时代和最困难的融资环境的时候十年。

BLV invests in companies with highly innovative platforms (biological or technological), developing novel therapeutics addressing large patient populations / major unmet medical needs, supported by strong data packages. The firm prefers to lead rounds – working closely with a company’s leadership team to complete diligence, negotiate equitable terms, secure the syndicate, and close the round with speed and efficiency..

BLV投资于具有高度创新平台（生物或技术）的公司，开发针对大量患者群体/主要未满足医疗需求的新型疗法，并提供强大的数据包支持。公司更愿意领导回合-与公司领导团队密切合作，完成勤奋，谈判公平条款，确保集团安全，并以快速和高效的方式结束回合。。

“Innovation never stops, even when financing does. The recent COVID-19 global pandemic proved that the pace of biopharmaceutical innovation is rapidly accelerating. The 2007-2008 Global Financial Crisis and the subsequent years of biopharma sector downturn proved that venture firms that continue to invest in breakthrough platforms – especially during financial downturns – can help make a meaningful impact on patients while generating strong financial returns,” said Founding and Managing Partner Kouki Harasaki, Ph.D.

“即使融资确实如此，创新也永远不会停止。最近的新型冠状病毒肺炎全球流行病证明，生物制药创新的步伐正在迅速加快.2007-2008年全球金融危机和随后几年的生物制药行业衰退证明，继续投资突破性平台的风险公司-特别是在金融衰退期间-可以帮助我创始和管理合作伙伴Kouki Harasaki博士说，在产生强大的财务回报的同时，对患者产生了巨大的影响。

“The best way to help Founders and CEOs right now is to partner with them to secure strong syndicates and close rounds. Post-investment, investors must be able to provide interdisciplinary support – more than ever – to help their companies advance programs through preclinical and clinical milestones in a capital-efficient manner.

“现在帮助创始人和首席执行官的最佳方法是与他们合作以确保强大的集团和密切关注。投资后，投资者必须能够提供跨学科支持-比以往任何时候都更多-帮助他们的公司通过临床前推进计划和临床里程碑以资本有效的方式。

We are incredibly fortunate to be supported by Limited Partners who have the heart to share our patient-centric mission, the perception to understand the unmet needs we are targeting, the trust in our approach to address them, and the vision to see the potential that will be realized together going forward.”.

我们非常幸运地得到有限合作伙伴的支持，这些合作伙伴有心分享我们以患者为中心的使命，理解我们所针对的未满足需求的看法，对我们解决这些问题的方法的信任以及看到潜力的愿景将在未来一起实现“。

Bioluminescence Ventures’ portfolio currently consists of multiple companies including:

Bioluminescence Ventures的产品组合目前由多家公司组成，包括：

Ensoma

Ensoma

Nido Biosciences

巢生物科学

ReCode Therapeutics

ReCode Therapeutics

SURGE Therapeutics

激增疗法

Bioluminescence Ventures is currently assembling an exceptional venture team with experience across biomedical research, biomedical engineering, translational science, clinical development, and biopharmaceutical M&A and IPO advisory. In addition, the firm has recruited world-renown academic and industry advisors.

Bioluminescence Ventures目前正在组建一个卓越的风险团队，拥有生物医学研究，生物医学工程，转化科学，临床开发以及生物制药M＆A和IPO咨询方面的经验。此外，该公司还招募了世界知名的学术和行业顾问。

BLV will announce the initial venture team and advisory board in the coming weeks..

BLV将在未来几周内公布初始风险团队和咨询委员会。。

“Bioluminescence is light emitted by living beings. It is a metaphor for our guiding light: patient impact. We see this light radiating from our mission-driven founders and CEOs,” said Dr. Harasaki. “We aim to support them with our time, energy, interdisciplinary expertise, and capital to make that light shine brighter.”.

Harasaki博士说：“生物发光是生物体发出的光，它是我们引导光的隐喻：患者的影响，我们看到这种光从我们的任务驱动的创始人和首席执行官那里辐射出来。“我们的目标是通过我们的时间，精力，跨学科专业知识和资本来支持他们，使灯光更加明亮。”。

About Kouki Harasaki, Bioluminescence Ventures Founding / Managing Partner

关于Kouki Harasaki，Bioluminescence Ventures创始/管理合作伙伴

Kouki Harasaki, Ph.D., MBA, has over 20 years of biomedical science experience working across major health systems, research institutes, biopharmaceutical corporations, technology companies, and venture capital firms. Prior to founding Bioluminescence Ventures, he was Managing Director at M12 / Microsoft Ventures, where he led Life Sciences investments and helped develop Microsoft corporate strategy in the field.

Kouki Harasaki博士，MBA，拥有20多年的生物医学科学经验，在主要卫生系统，研究机构，生物制药公司，技术公司和风险投资公司工作。在成立生物发光企业之前，他曾担任M12/Microsoft Ventures的总经理，在那里他领导生命科学投资并帮助制定该领域的微软公司战略。

Before M12, Dr. Harasaki was a senior Partner at Andreessen Horowitz (Bio Fund). Prior to his time in venture, Dr. Harasaki held Drug Discovery, Animal Pharmacology, Strategy, Finance, and Business Development roles at Novartis AG and Baxalta/Shire. He has led over $600M in financing deals that have funded over 25 therapeutics programs across stages (discovery to marketed), across therapeutic areas (CVM, Immunology, Oncology, Neuro/CNS), and across modalities (small molecules, biologics, genome editors, cell therapies).

在M12之前，Harasaki博士是Andreessen Horowitz（生物基金）的高级合作伙伴。在成立之前，Harasaki博士在诺华股份有限公司和Baxalta/Shire担任药物发现，动物药理学，战略，金融和业务发展角色。他已经领导了超过6亿美元的融资交易，这些交易资助了超过25个跨阶段（发现到销售），跨治疗领域（CVM，免疫学，肿瘤学，神经/中枢神经系统）和跨模式（小分子，生物制剂，基因组编辑），细胞疗法）。

He earned a BA in Molecular/Cell Biology from Cornell University, a PhD in Clinical Biochemistry from the University of Cambridge (Wellcome Trust Fellow), and an MBA from Harvard Business School (Robert S. Kaplan Fellow)..

他获得康奈尔大学分子/细胞生物学学士学位，剑桥大学临床生物化学博士学位（Wellcome Trust Fellow）和哈佛商学院MBA（Robert S.Kaplan Fellow）。。

Dr. Harasaki currently serves on the Boards of ReCode Therapeutics, Ensoma, Nido Biosciences, and SURGE Therapeutics.

Harasaki博士目前担任ReCode Therapeutics，Ensoma，Nido Biosciences和SURGE Therapeutics的董事会成员。

About Bioluminescence Ventures (BLV)

关于生物发光企业（BLV）

Bioluminescence is a leading US biotechnology venture capital firm investing in the future of medicine. We are inspired by the accelerating pace of biomedical innovation and its recent impact on humanity. We are mission-driven – investing our time, energy, and capital into translating transformative science into next-generation medicines that will impact patients.

生物发光是美国领先的生物技术风险投资公司，投资于医学的未来。我们受到生物医学创新加速步伐及其近期对人类影响的启发。我们是使命驱动的-将我们的时间，精力和资本投入到将变革性科学转化为影响患者的下一代药物中。

We believe that, as long as we continue to succeed in this endeavor, then strong financial returns will follow. The firm focuses investments on four areas: Breakthrough Biology, Drug Discovery Platforms, Genetic Medicines Platforms, and Computational Biology Platforms. For more information, please visit Bioluminescence.com..

我们相信，只要我们继续在这项努力中取得成功，那么就会有强大的财务回报。该公司将投资重点放在四个领域：突破性生物学，药物发现平台，遗传药物平台和计算生物学平台。欲了解更多信息，请访问Bioluminescence.com。。

Foley & Lardner acted as counsel to Bioluminescence Ventures for fund formation.

Foley＆Lardner担任Bioluminescence Ventures基金组建顾问。